Evaluating the effect of mirtazapine on anxiety in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trial

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 64 人开始时间: 待定最近更新: 2022年6月27日

适应症

试验速览

暂无简介。

•Men and women over 17 years old
•Patient with Parkinson's disease according to UKPDSBB criteria
•Patient with mild/moderate Parkinson’s disease according to Hoehn and Yahr Scale (HY score = 1-3)
•Self-report or clinical diagnosis of anxiety
•Patients who have signed informed consent to participate in the study

•Pregnant and lactating women
•Parkinson's patients with onset of disease in less than 1 year
•Unstable medication for Parkinson's disease during the last two weeks
•Parkinson's patients with DBS
•Patients with other neurodegenerative diseases like multiple system atrophy (MSA), Huntington's and etc.
•Patients with major depressive disorder
•A history of using SSRIs, SNRIs, benzodiazepines and ß-blockers during the last 4 weeks
•A history of using MAO inhibitors
•A history of alcohol and substance abuse
•A history of acute stress during the last 3 months
•A history of suicide
•A history of cardiovascular diseases
•A history of liver disorders
•A history of kidney disorders

发起方